|
US6482404B1
(en)
|
1989-10-12 |
2002-11-19 |
David James White |
Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
|
|
US5866402A
(en)
*
|
1995-05-05 |
1999-02-02 |
Chiron Corporation |
Chimeric MCP and DAF proteins with cell surface localizing domain
|
|
FR2736916B1
(fr)
*
|
1995-07-21 |
1997-09-19 |
Univ Paris Curie |
Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
|
|
ATE286743T1
(de)
*
|
1997-10-31 |
2005-01-15 |
Us Army |
Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
|
|
CN101298481A
(zh)
*
|
1998-02-20 |
2008-11-05 |
吉宁特有限公司 |
补体活化的抑制剂
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
US6956107B2
(en)
*
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
US6297024B1
(en)
|
1998-10-15 |
2001-10-02 |
Cell Activation, Inc. |
Methods for assessing complement activation
|
|
US6235494B1
(en)
|
1999-02-08 |
2001-05-22 |
The Scripps Research Institute |
Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
|
|
CA2389633A1
(en)
*
|
1999-11-01 |
2001-05-10 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
|
US6534058B2
(en)
|
2000-10-10 |
2003-03-18 |
Tanox, Inc. |
Anti-C5 monoclonal antibodies
|
|
US6820011B2
(en)
*
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
|
JP4476623B2
(ja)
*
|
2001-06-08 |
2010-06-09 |
ノバルティス アーゲー |
インスリン産生細胞移植片拒絶の処置または予防
|
|
US20060153839A1
(en)
*
|
2002-09-16 |
2006-07-13 |
Elusys Therapeutics, Inc. |
Production of bispecific molecules using polyethylene glycol linkers
|
|
CA2505601C
(en)
*
|
2002-11-15 |
2014-10-28 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
|
US8124097B2
(en)
|
2004-01-21 |
2012-02-28 |
Case Western Reserve University |
Hybrid and chimeric polypeptides that regulate activation of complement
|
|
BRPI0506629A
(pt)
*
|
2004-02-10 |
2007-05-02 |
Univ Colorado |
inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
|
|
US8703693B2
(en)
*
|
2004-03-31 |
2014-04-22 |
The Feinstein Institute For Medical Research |
Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
|
|
ATE500836T1
(de)
|
2004-03-31 |
2011-03-15 |
The Feinstein Inst Medical Res |
Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung
|
|
JP5707024B2
(ja)
*
|
2005-05-26 |
2015-04-22 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ |
外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
|
|
HUE026423T2
(en)
*
|
2005-11-04 |
2016-05-30 |
Genentech Inc |
Use of complement biosynthetic pathway inhibitors for treating eye diseases
|
|
EP2044111B1
(en)
|
2006-06-21 |
2014-08-13 |
MUSC Foundation For Research Development |
Targeting complement factor h for treatment of diseases
|
|
SI2097455T1
(sl)
*
|
2006-11-02 |
2015-03-31 |
Genentech, Inc. |
Humanizirana protitelesa proti faktorju tipa d
|
|
US20100120665A1
(en)
*
|
2007-03-01 |
2010-05-13 |
Advanced Vision Therapies, Inc. |
Treatment of diseases characterized by inflammation
|
|
EP2565207A3
(en)
*
|
2007-03-14 |
2013-06-12 |
Alexion Cambridge Corporation |
Humaneered Anti-Factor B Antibody
|
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
WO2009151634A1
(en)
*
|
2008-06-12 |
2009-12-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
|
RS20120461A1
(sr)
|
2009-07-02 |
2013-06-28 |
Musc Foundation For Research Development |
Metode za stimulaciju regeneracije jetre
|
|
NZ600393A
(en)
|
2009-11-05 |
2014-08-29 |
Alexion Cambridge Corp |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
|
CN102234332B
(zh)
*
|
2010-04-26 |
2014-12-17 |
浙江海正药业股份有限公司 |
一种重组人血白蛋白及其融合蛋白的分离纯化工艺
|
|
MX2012013233A
(es)
|
2010-05-14 |
2013-05-20 |
Univ Colorado Regents |
Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
|
|
CN103249432A
(zh)
|
2010-06-22 |
2013-08-14 |
科罗拉多大学董事会,法人团体 |
补体成分3的C3d片段的抗体
|
|
BR112013005116A2
(pt)
|
2010-09-03 |
2019-09-24 |
Stem Centrx Inc |
moduladores e métodos de uso
|
|
US10039802B2
(en)
|
2011-06-22 |
2018-08-07 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
JP6244350B2
(ja)
*
|
2012-04-03 |
2017-12-06 |
ノーベルメッド セラピューティクス インコーポレイテッド． |
ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
|
|
WO2013177035A2
(en)
|
2012-05-24 |
2013-11-28 |
Alexion Pharmaceuticals, Inc. |
Humaneered anti-factor b antibody
|
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
|
AU2013302441B2
(en)
|
2012-08-17 |
2018-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for detecting complement activation
|
|
CA2920666A1
(en)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
Compositions and method for treating complement-associated conditions
|
|
SG11201606983SA
(en)
|
2014-02-27 |
2016-09-29 |
Allergan Inc |
COMPLEMENT FACTOR Bb ANTIBODIES
|
|
CR20160561A
(es)
|
2014-05-01 |
2017-05-03 |
Genentech Inc |
Variantes del anticuerpo anti-factor d y sus usos
|
|
EP3234598B1
(en)
|
2014-12-18 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Assay and method for determining cdc eliciting antibodies
|
|
US10988519B2
(en)
|
2015-09-24 |
2021-04-27 |
The Trustees Of The University Of Pennsylvania |
Composition and method for treating complement-mediated disease
|
|
US10654932B2
(en)
|
2015-10-30 |
2020-05-19 |
Genentech, Inc. |
Anti-factor D antibody variant conjugates and uses thereof
|
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
|
US10640540B2
(en)
|
2015-12-23 |
2020-05-05 |
Greenovation Biotech Gmbh |
Polypeptides for inhibiting complement activation
|
|
JP7068203B2
(ja)
|
2016-06-28 |
2022-05-16 |
ウニベルジテート ウルム |
補体阻害剤及びその使用
|
|
GB201800620D0
(en)
|
2018-01-15 |
2018-02-28 |
Univ Manchester |
C3b Binding Polypeptide
|
|
US20220195012A1
(en)
*
|
2019-04-13 |
2022-06-23 |
National Centre For Cell Science |
Daf-mcp chimeric proteins, process to manufacture the same and use of the chimeric protein for treating pathological conditions involving the complement system
|